Pyxis Oncology
PYXSPYXS · Stock Price
Historical price data
Overview
Pyxis Oncology's mission is to liberate science to cure patients with cancer through a disruptive approach that improves and extends life. The company has achieved key milestones including positive preliminary Phase 1 data for its lead ADC, MICVO, and securing FDA Fast Track Designation for recurrent/metastatic head and neck squamous cell carcinoma. Its strategy centers on developing a portfolio of next-generation ADCs and immunotherapies, with a core focus on novel extracellular matrix targets to overcome limitations of conventional therapies. Pyxis is publicly traded, maintains a lean operational structure, and is led by an experienced management team with a track record in oncology drug development.
Technology Platform
A platform for designing novel antibody-drug conjugates (ADCs) focused on targeting extracellular matrix proteins in the tumor microenvironment, and developing immunotherapies to overcome immune suppression.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| APX005M + Pembrolizumab | Melanoma | Phase 1/2 | |
| PYX-106 | Solid Tumor | Phase 1 | |
| APX005M treatment for recurrent or refractory primary malign... | Glioblastoma Multiforme | Phase 1 | |
| PYX-201 | Solid Tumor | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Pyxis competes in the crowded ADC and IO space, primarily differentiated by its first-in-class targeting of the extracellular matrix protein EDB+FN. It faces indirect competition from all HNSCC therapies and direct competition from large pharma with vast ADC platforms (e.g., AstraZeneca, Pfizer). Its small size and single clinical asset make it vulnerable to competitive pressure and clinical setbacks.